GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » 50-Day SMA

SBFM (Sunshine Biopharma) 50-Day SMA : $2.61 (As of Mar. 16, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2025-03-16), Sunshine Biopharma's 50-Day SMA is $2.61. It's 20-Day SMA is $2.30 and 200-Day SMA is $3.96.


Competitive Comparison of Sunshine Biopharma's 50-Day SMA

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's 50-Day SMA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's 50-Day SMA falls into.



Sunshine Biopharma  (NAS:SBFM) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Biopharma  (NAS:SBFM) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Sunshine Biopharma 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma Business Description

Traded in Other Exchanges
N/A
Address
1177 Avenue of the Americas, 5th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3